Kura Oncology (NASDAQ:KURA) Insider Teresa Brophy Bair Sells 11,208 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 11,208 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $94,819.68. Following the transaction, the insider owned 226,931 shares of the company’s stock, valued at approximately $1,919,836.26. This represents a 4.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Teresa Brophy Bair also recently made the following trade(s):

• On Friday, November 14th, Teresa Brophy Bair sold 8,804 shares of Kura Oncology stock. The shares were sold at an average price of $11.18, for a total value of $98,428.72.

Kura Oncology Trading Down 1.2%

Shares of KURA stock opened at $8.47 on Wednesday. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $12.49. The firm has a market capitalization of $737.06 million, a PE ratio of -3.42 and a beta of 0.25. The stock has a fifty day moving average of $10.33 and a two-hundred day moving average of $9.05. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. As a group, research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

Hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC increased its stake in Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after acquiring an additional 9,958 shares during the period. Brevan Howard Capital Management LP purchased a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $80,000. Finally, Merit Financial Group LLC purchased a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $89,000.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Negative Sentiment: Teresa Brophy Bair (insider) sold 11,208 shares at an average price of $8.46 for proceeds of $94,819.68; her post-sale holdings are 226,931 shares (down ~4.71%). Read More.
• Negative Sentiment: Francis Burrows (insider) sold 1,311 shares at $8.46 for proceeds of $11,091.06; post-sale holdings 32,424 shares (down ~3.89%). Read More.
• Negative Sentiment: Thomas James Doyle (SVP) sold 7,142 shares at $8.46 for proceeds of $60,421.32; post-sale holdings 145,167 shares (down ~4.69%). Read More.
• Negative Sentiment: Mollie Leoni (insider) sold 8,180 shares at $8.46 for proceeds of $69,202.80; post-sale holdings 267,274 shares (down ~2.97%). Read More.
• Negative Sentiment: Kathleen Ford (COO) sold 1,813 shares at $8.46 for proceeds of $15,337.98; post-sale holdings 153,560 shares (down ~1.17%). Read More.

Wall Street Analyst Weigh In

Several brokerages recently commented on KURA. UBS Group boosted their target price on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Barclays reissued an “overweight” rating and issued a $28.00 price objective (up previously from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Wedbush reaffirmed an “outperform” rating and set a $38.00 target price (up previously from $36.00) on shares of Kura Oncology in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Finally, JMP Securities reissued a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, October 20th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $28.00.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.